文献速递流行病学与生物统计真实世界研究与卫生经济

真实世界使用非甾体抗炎药与急性心肌梗死风险:个体患者数据的贝叶斯Meta分析

Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.
PubMed 文献 · BMJ · 2017-05-09

该研究基于加拿大和欧洲医疗数据库,纳入446763例个体(其中61460例发生急性心肌梗死),采用贝叶斯个体患者数据Meta分析。结果显示所有非甾体抗炎药(包括萘普生)均与急性心肌梗死风险增加相关,使用第一周风险最高,且剂量越高风险越大。塞来昔布风险与传统非甾体抗炎药相当,低于罗非昔布。

要点

  • 使用任何剂量非甾体抗炎药1周、1月或超过1月均与心肌梗死风险增加相关。
  • 使用1至7天时,心肌梗死风险增加的比值比>1.0的后验概率:塞来昔布92%、布洛芬97%、双氯芬酸/萘普生/罗非昔布99%。
  • 所有非甾体抗炎药(包括萘普生)均与急性心肌梗死风险增加相关,使用第一个月风险最高,剂量越高风险越大。

核心结论

  • 所有非甾体抗炎药(包括萘普生)均与急性心肌梗死风险增加相关。
  • 塞来昔布的心肌梗死风险与传统非甾体抗炎药相当,低于罗非昔布。
  • 风险在非甾体抗炎药使用第一个月最高,且剂量越高风险越大。

研究设计与样本

  • 系统综述及一阶段贝叶斯个体患者数据Meta分析。
  • 数据来源为加拿大和欧洲的医疗数据库研究。
  • 纳入标准包括:记录急性心肌梗死为特定结局、研究选择性环氧合酶-2抑制剂(包括罗非昔布)和传统非甾体抗炎药、比较使用者与非使用者、允许时间依赖分析、最小化混杂和错分偏倚。
  • 共纳入446763例个体,其中61460例发生急性心肌梗死。

主要发现

  • 使用任何剂量非甾体抗炎药1周、1月或超过1月均与心肌梗死风险增加相关。
  • 使用1至7天时,心肌梗死风险增加(比值比>1.0)的后验概率:塞来昔布92%、布洛芬97%、双氯芬酸/萘普生/罗非昔布99%。
  • 对应比值比(95%可信区间):塞来昔布1.24(0.91至1.82)、布洛芬1.48(1.00至2.26)、双氯芬酸1.50(1.06至2.04)、萘普生1.53(1.07至2.33)、罗非昔布1.58(1.07至2.17)。
  • 非甾体抗炎药剂量越高,心肌梗死风险越大。
  • 使用超过1月时,风险未超过较短使用时间的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To characterise the determinants, time course, and risks of acute myocardial infarction associated with use of oral non-steroidal anti-inflammatory drugs (NSAIDs).Design Systematic review followed by a one stage bayesian individual patient data meta-analysis.Data sources Studies from Canadian and European healthcare databases.Review methods Eligible studies were sourced from computerised drug prescription or medical databases, conducted in the general or an elderly population, documented acute myocardial infarction as specific outcome, studied selective cyclo-oxygenase-2 inhibitors (including rofecoxib) and traditional NSAIDs, compared risk of acute myocardial infarction in NSAID users with non-users, allowed for time dependent analyses, and minimised effects of confounding and misclassification bias. Exposure and outcomes Drug exposure was modelled as an indicator variable incorporating the specific NSAID, its recency, duration of use, and dose. The outcome measures were the summary adjusted odds ratios of first acute myocardial infarction after study entry for each category of NSAID use at index date (date of acute myocardial infarction for cases, matched date for controls) versus non-use in the preceding year and the posterior probability of acute myocardial infarction.Results A cohort of 446 763 individuals including 61 460 with acute myocardial infarction was acquired. Taking any dose of NSAIDs for one week, one month, or more than a month was associated with an increased risk of myocardial infarction. With use for one to seven days the probability of increased myocardial infarction risk (posterior probability of odds ratio >1.0) was 92% for celecoxib, 97% for ibuprofen, and 99% for diclofenac, naproxen, and rofecoxib. The corresponding odds ratios (95% credible intervals) were 1.24 (0.91 to 1.82) for celecoxib, 1.48 (1.00 to 2.26) for ibuprofen, 1.50 (1.06 to 2.04) for diclofenac, 1.53 (1.07 to 2.33) for naproxen, and 1.58 (1.07 to 2.17) for rofecoxib. Greater risk of myocardial infarction was documented for higher dose of NSAIDs. With use for longer than one month, risks did not appear to exceed those associated with shorter durations.Conclusions All NSAIDs, including naproxen, were found to be associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib was comparable to that of traditional NSAIDS and was lower than for rofecoxib. Risk was greatest during the first month of NSAID use and with higher doses.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017. PMID: 28487435. doi:10.1136/bmj.j1909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。